⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OTLK News
Outlook Therapeutics, Inc. Common Stock
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
globenewswire.com
OTLK
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
globenewswire.com
OTLK
2026 Back of the Eye Disorders Market Research Report (2nd Edition): A Development Pipeline Consisting of ~690 Approved or Clinical-Stage Therapeutic Candidates
globenewswire.com
KODK
OTLK
ALDX
OCUL
REGN
ABBV
NVS
BHC
SUN
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
globenewswire.com
OTLK
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
globenewswire.com
OTLK
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
accessnewswire.com
AIM
AKTX
CNSP
DARE
NVNO
ERNA
GRI
MBRX
OTLK
Form 8-K
sec.gov
OTLK
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
globenewswire.com
OTLK